1.1Focal ablation with PKC inhibition
Image guidance positions a microwave antenna inside a selected liver lesion. Microwave energy heats the lesion and a planned margin of surrounding tissue, while a systemic small molecule inhibits PKC.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
Image guidance positions a microwave antenna inside a selected liver lesion. Microwave energy heats the lesion and a planned margin of surrounding tissue, while a systemic small molecule inhibits PKC.
A soluble bispecific protein binds a melanocyte-lineage peptide presented by a specific human leukocyte antigen and binds CD3 on T cells. This interaction directs T-cell killing toward cells that display the peptide, while a separate small molecule inhibits PKC.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A laboratory assay applies PKC and c-MET inhibition to organoids derived from hepatic uveal melanoma metastases. Replicate wells contain organoids embedded in a three-dimensional hydrogel and receive vehicle, either inhibitor alone, or both inhibitors together. Automated microscopy measures organoid area over time, and an endpoint viability assay measures the fraction of cells that remain metabolically active.
Crizotinib, a small molecule that inhibits c-MET kinase activity, serves as the c-MET inhibitor alongside a separately formulated PKC inhibitor. A hepatic metastasis cell assay compares the pair with matched single-agent and vehicle controls. The assay measures phosphorylated c-MET and a phosphorylated PKC substrate, alongside the corresponding total protein levels, to track activity at both targets.
Parallel hepatic uveal melanoma cultures receive the two inhibitors simultaneously, receive the PKC inhibitor 24 hours before the c-MET inhibitor, or receive the c-MET inhibitor 24 hours before the PKC inhibitor. Each inhibitor remains in the culture medium after addition, and matched wells receive vehicle at the same handling times. Viability and target phosphorylation are measured immediately before the staggered second addition and 48 hours after both inhibitors are present.
A microfluidic liver culture device places a hepatic uveal melanoma spheroid in a tissue chamber adjacent to a perfusion channel. A pump drives culture medium through the channel, and separate inlet reservoirs supply the PKC inhibitor and the c-MET inhibitor through a mixing junction upstream of the chamber. Inlet and outlet samples provide drug concentration measurements, and an optical window permits serial imaging of the spheroid.
Image analysis software processes baseline and follow-up contrast-enhanced liver scans acquired during treatment with the two inhibitors. A registration step aligns the scans, and a segmentation model generates editable masks for individual hepatic lesions. After a reviewer confirms the masks, the software records each lesion volume, sums the volumes by visit, and plots the total against treatment dates.
A liquid handler dispenses the PKC inhibitor along one axis of a multiwell plate and the c-MET inhibitor along the other axis to create a two-dimensional concentration matrix. Wells contain hepatic uveal melanoma cells, and the plate includes vehicle controls and concentration series for each inhibitor alone. A plate reader records viability, and analysis software normalizes the readings to the vehicle controls and maps the response at each concentration pair.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
Treatment of a subject with a therapeutically effective amount of the peptide can include a single treatment or, preferably, can include a series of treatments.A · US 2009/0155236 A1 · ¶ 117
The method comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound that modulates MET.B · US 11,116,759 B2 · ¶ 7
An empty cell means only that no passage was reproduced there.
This invention relates to amino acid sequences of annexin V and to the use of these sequences in the regulating cellular responses mediated by delta protein kinase C.A · US 2009/0155236 A1 · ¶ 1
There remains a need in the art for therapeutic agents capable of regulating the activity of delta PKC, particularly for modulating the activity of delta PKC in its role associated with ischemia, in order to reduce the deleterious effects of ischemia and of reperfusion injury.A · US 2009/0155236 A1 · ¶ 8
Thus, a need remains for methods of treating ocular melanoma, particularly by inhibiting MET.B · US 11,116,759 B2 · ¶ 6
The melanoma can be ocular melanoma, and more particularly choroidal melanoma or iris melanoma.B · US 11,116,759 B2 · ¶ 7
patent.fyi, US 2026/0355183 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355183/, SHA-256 b6d06654afba33202ce651d9ea77a129afaf0b0b2e591e8dbf4df2272bb1a7ca